![Thomas Buchholz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Buchholz
Director/Board Member at Nucleix Ltd.
Profile
Thomas Buchholz is currently the Director at Nucleix Ltd.
He completed his undergraduate degree at Bucknell University and his doctorate at Tufts University School of Medicine.
Thomas Buchholz active positions
Companies | Position | Start |
---|---|---|
Nucleix Ltd.
![]() Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Director/Board Member | 10/05/2020 |
Training of Thomas Buchholz
Bucknell University | Undergraduate Degree |
Tufts University School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Nucleix Ltd.
![]() Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
- Stock Market
- Insiders
- Thomas Buchholz